Neuroactive steroids and compositions thereof
US-11643434-B2 · May 9, 2023 · US
Small molecule inhibitors of NF-kB inducing kinase
US11827634B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11827634-B2 |
| Application number | US-202117549057-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 13, 2021 |
| Priority date | May 31, 2019 |
| Publication date | Nov 28, 2023 |
| Grant date | Nov 28, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, immunodermatologic disorders such as palmoplantar pustulosis and hidradenitis suppurativa, and metabolic disorders such as obesity and diabetes.
First claim
Opening claim text (preview).
What is claimed: 1. A compound selected from the group consisting of: or a pharmaceutically acceptable salt thereof. 2. The compound of claim 1 , having the following structure or a pharmaceutically acceptable salt thereof. 3. The compound of claim 1 , having the following structure or a pharmaceutically acceptable salt thereof. 4. The compound of claim 1 , having the following structure or a pharmaceutically acceptable salt thereof. 5. The compound of claim 1 , having the following structure or a pharmaceutically acceptable salt thereof. 6. The compound of claim 1 , having the following structure or a pharmaceutically acceptable salt thereof. 7. The compound of claim 1 , having the following structure or a pharmaceutically acceptable salt thereof. 8. The compound of claim 1 , having the following structure or a pharmaceutically acceptable salt thereof. 9. The compound of claim 1 , having the following structure or a pharmaceutically acceptable salt thereof. 10. The compound of claim 1 , having the following structure or a pharmaceutically acceptable salt thereof. 11. The compound of claim 1 , having the following structure or a pharmaceutically acceptable salt thereof. 12. The compound of claim 1 , having the following structure or a pharmaceutically acceptable salt thereof. 13. The compound of claim 1 , having the following structure or a pharmaceutically acceptable salt thereof. 14. The compound of claim 1 , having the following structure or a pharmaceutically acceptable salt thereof. 15. The compound of claim 1 , having the following structure or a pharmaceutically acceptable salt thereof. 16. The compound of claim 1 , having the following structure or a pharmaceutically acceptable salt thereof. 17. The compound of claim 1 , having the following structure or a pharmaceutically acceptable salt thereof. 18. The compound of claim 1 , having the following structure or a pharmaceutically acceptable salt thereof. 19. The compound of claim 1 , having the following structure or a pharmaceutically acceptable salt thereof. 20. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound or pharmaceutically acceptable salt thereof as claimed in claim 1 . 21. The compound of claim 1 , having the following structure 22. The compound of claim 1 , having the following structure 23. The compound of claim 1 , having the following structure 24. The compound of claim 1 , having the following structure 25. The compound of claim 1 , having the following structure 26. The compound of claim 1 , having the following structure 27. The compound of claim 1 , having the following structure 28. The compound of claim 1 , having the following structure 29. The compound of claim 1 , having the following structure 30. The compound of claim 1 , having the following structure 31. The compound of claim 1 , having the following structure
Assignees
Inventors
Classifications
Drugs for dermatological disorders · CPC title
for hyperglycaemia, e.g. antidiabetics · CPC title
Anorexiants; Antiobesity agents · CPC title
Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11827634B2 cover?
- The present invention relates to compounds that inhibit NIK and pharmaceutical compositions comprising such compounds and methods of using the same. These compounds and pharmaceutical compositions are envisaged to be useful for preventing or treating diseases such as cancer (such as B-cell malignancies including leukemias, lymphomas and myeloma), inflammatory disorders, autoimmune disorders, im…
- Who is the assignee on this patent?
- Janssen Pharmaceutica Nv
- What technology area does this patent fall under?
- Primary CPC classification C07D487/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).